Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis

• DOI: 10.1371/journal.pone.0275681
• Publication Date: 2022-10-19T17:32:22Z
• Authors: Lisa Scarton; Ara Jo; Zhigang Xie; LaToya J. O’Neal; Juan M. Munoz Pena; Thomas J. George; Jiang Bian
• Keywords: Male; Science; Hypoglycemic Agents (therapeutic use); Pancreatic Neoplasms (drug therapy); Medicare; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; Diabetes Mellitus; Type 2 (complications); Humans; Hypoglycemic Agents; Aged; Retrospective Studies; United States (epidemiology); Q; R; United States; Metformin; 3. Good health; Pancreatic Neoplasms; Diabetes Mellitus, Type 2; Medicine; Metformin (therapeutic use); Research Article

Cancer is a major health problem in the U.S and type 2 diabetes mellitus (T2DM) known to increase risk for development of many cancers. Metformin, first-line therapy treating T2DM, increasingly being used its anticancer effects; however, literature limited on effect metformin dose overall survival patients with stage IV cancer. Overall was defined as time interval from date diagnosis last follow-up or death any cause. Subjects who were alive December 31, 2016 censored. In this cohort study we examined relationship between persons both T2DM lung, breast, colorectal, prostate, pancreas We retrospective design Cox proportional hazards regression analysis 2007–2016 Surveillance Epidemiology End Results-Medicare (SEER) dataset. Of 7,725 patients, 2,981(38.5%) had been prescribed metformin. Patients significantly better unadjusted (Unadjusted HR, 0.73; 95% CI, 0.69–0.76; p < 0.001) adjusted models (adjusted 0.77; 0.73–0.81; 0.001). The took average daily ≥ 1000mg not statistically significant (aHR, 1.00; 0.93–1.08; = 0.90). Metformin use regardless associated increased older adults